

HR 6963

Accelerated Approval Integrity Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 7, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 8, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/6963>

Sponsor

Name: Rep. Pallone, Frank, Jr. [D-NJ-6]

Party: Democratic • **State:** NJ • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Maloney, Carolyn B. [D-NY-12]	D · NY		Mar 16, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 8, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Mar 7, 2022)

Accelerated Approval Integrity Act of 2022

This bill establishes requirements relating to postapproval studies for drugs that receive accelerated approval for serious or life-threatening diseases or conditions, such as requiring product sponsors to agree in advance to conduct such studies and terminating product approval if certain benchmarks are not met.

Actions Timeline

- **Mar 8, 2022:** Referred to the Subcommittee on Health.
- **Mar 7, 2022:** Introduced in House
- **Mar 7, 2022:** Referred to the House Committee on Energy and Commerce.